🔎 Trials Near Me

Gara Jalqabaatti › Diffuse Large B-Cell Lymphoma › Florida

Qorannoo klinikaalii Diffuse Large B-Cell Lymphoma Florida keessatti

Qorannoo 23 Diffuse Large B-Cell Lymphoma f Florida keessatti hirmaatuu jiru.

Magaalota Florida keessatti

Takkalaa qorannoo (Ingiliffa)

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Mayo Clinic Jacksonville, Jacksonville
  • Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
  • Tampa General Hospital Cancer Institute, Tampa
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05006716

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

  • Mayo Clinic in Florida, Jacksonville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06834373

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Miami Cancer Institute at Baptist Health, Inc., Miami
  • Advent Health Cancer Institute, Orlando
  • Orlando Health Cancer Institute, Orlando
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06500273

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  • Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton
  • Clermont Oncology Center ( Site 0174), Clermont
  • BRP-Hialeah Hospital ( Site 0182), Hialeah
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT05139017

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  • Clermont Oncology Center ( Site 0182), Clermont
  • Bioresearch Partner ( Site 0157), Hialeah
  • Orlando Health Cancer Institute ( Site 0169), Ocoee
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06717347

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130), Boca Raton
  • Baptist MD Anderson Cancer Center ( Site 0176), Jacksonville
  • Mount Sinai Braman Comprehensive Cancer Center ( Site 0140), Miami Beach
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06890884

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  • Mayo Clinic Jacksonville, Jacksonville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06091865

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • University of Miami - Sylvester Cancer Center, Miami
  • Florida Cancer Specialists - Sarasota, Sarasota
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07226843

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Johns Hopkins All Children's Hospital ( Site 1025), St. Petersburg
Namoota walitti qabaa jiraSadarkaa 1/2
6 Months – 25 Years · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT06395103

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

  • Moffitt Cancer Center, Tampa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT05757219

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  • North Florida/ South Georgia VA Medical Center, Gainesville
  • Mount Sinai Comprehensive Cancer Center, Miami
  • Orlando Health Cancer Institute, Orlando
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT06806033

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Mayo Clinic, Clinical Trials Referral Office, Jacksonville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 13 hanga 90 · Saalaa hunda · Haaromfame 06-Hag-2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Mayo Clinic Florida, Jacksonville
  • AdventHealth, Orlando
  • Moffitt Cancer Center, Tampa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT07188558

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

  • Mayo Clinic, Jacksonville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT07424833

DALY II USA/ MB-CART2019.1 for DLBCL

  • Baptist Health Miami Cancer Institute, Miami
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT04792489

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  • Moffitt Cancer Center, Tampa
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ado-2026 · NCT06015880

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • University of Miami, Miami
  • Florida Cancer Specialists, Sarasota
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ado-2026 · NCT05131022

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • ASCLEPES Research Centers, Weeki Wachee
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 hanga 95 · Saalaa hunda · Haaromfame 15-Elb-2026 · NCT04329728

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

  • University of Miami Sylvester Cancer Center, Miami
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Bit-2026 · NCT05800366

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

  • Mayo Clinic in Florida, Jacksonville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Gur-2026 · NCT06191887

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • UF Health Cancer Institute - Gainesville, Gainesville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Gur-2026 · NCT05633615

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Holy Cross Hospital, Fort Lauderdale
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Onk-2025 · NCT05890352

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • Florida Cancer Specialists, Sarasota
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2025 · NCT05780034

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.